Shingo Nakamura
Directeur/Bestuurslid bij REGiMMUNE Corp.
Profiel
Shingo Nakamura is currently working as a Director at REGiMMUNE Corp.
Previously, he worked as an Outside Director at PRISM BioLab Co., Ltd.
Mr. Nakamura has a graduate degree from Stanford University, an undergraduate degree from Waseda University, and an MBA from MIT Sloan School of Management.
Actieve functies van Shingo Nakamura
| Bedrijven | Functie | Begin |
|---|---|---|
REGiMMUNE Corp.
 REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Shingo Nakamura
| Bedrijven | Functie | Einde |
|---|---|---|
PRISM BioLab Co., Ltd.
 PRISM BioLab Co., Ltd. BiotechnologyHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan. | Directeur/Bestuurslid | - |
Opleiding van Shingo Nakamura
| MIT Sloan School of Management | Masters Business Admin |
| Stanford University | Graduate Degree |
| Waseda University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
PRISM BioLab Co., Ltd.
PRISM BioLab Co., Ltd. BiotechnologyHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan. | Health Technology |
